Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: A meta-analysis

Clinical Infectious Diseases

Volumn 41, Issue 3, 2005, Pages 327-333

  DiazGranados, Carlos A ^a,c   Zimmer, Shanta M ^a   Klein, Mitchel ^b   Jernigan, John A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c Fundacion Universitaria de Ciencias de la Salud   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BACTEREMIA; BACTERIAL INFECTION; CLINICAL TRIAL; COCHRANE LIBRARY; COMPARATIVE STUDY; DATA BASE; DISEASE SEVERITY; ENTEROCOCCUS; HUMAN; MEDLINE; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; REVIEW; SEPSIS; SYSTEMATIC REVIEW;

BACTEREMIA; ENTEROCOCCUS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; ODDS RATIO; VANCOMYCIN RESISTANCE;

EID: 22544433208     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/430909     Document Type: Review

References (45)

1. Emori TG, Gaynes RP. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Microbiol Rev 1993; 6:428-42.
2. Jones RN, Marshall SA, Pfaller MA, et al. Nosocomial enterococcal blood stream infections in the SCOPE Program: antimicrobial resistance, species occurrence, molecular testing results, and laboratory testing accuracy. SCOPE Hospital Study Group. Diagn Microbiol Infect Dis 1997; 29:95-102.
3. Pfaller MA, Jones RN, Doern GV, Kugler K. Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrob Agents Chemother 1998; 42:1762-70.
4. Low DE, Keller N, Barth A, Jones RN. Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of enterococci: results from the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001; 32(Suppl 2):S133-45.
5. Murray BE. Vancomycin-resistant enterococcal infections. N Engl J Med 2000; 342:710-21.
6. Recommendations for preventing the spread of vancomydn resistance. Hospital Infection Control Practices Advisory Committee (HICPAC). Infect Control Hosp Epidemiol 1995; 16:105-13.
7. Muto CA, Jernigan JA, Ostrowsky BE, et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus. Infect Control Hosp Epidemiol 2003; 24:362-86.
8. Dresser LD, Rybak MJ. The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials. Pharmacotherapy 1998; 18:456-62.
9. Chant C, Rybak MJ. Quinupristin/dalfopristin (RP 59500): a new streptogramin antibiotic. Ann Pharmacother 1995; 29:1022-7.
10. Louie A, Baltch AL, Ritz WJ, Smith RP, Asperilla M. Comparison of in vitro inhibitory and bactericidal activities of daptomycin (LY 146032) and four reference antibiotics, singly and in combination, against gentamicin-susceptible and high-level-gentamicin-resistant enterococci. Chemotherapy 1993; 39:302-9.
11. Lautenbach E, Bilker WB, Brennan PJ. Enterococcal bacteremia: risk factors for vancomycin resistance and predictors of mortality. Infect Control Hosp Epidemiol 1999; 20:318-23.
12. Stroud L, Edwards J, Danzing L, Culver D, Gaynes R. Risk factors for mortality associated with enterococcal bloodstream infections. Infect Control Hosp Epidemiol 1996; 17:576-80.
13. Edmond M. Cost-effectiveness of perirectal surveillance cultures for controlling vancomycin-resistant Entero. Infect Control Hosp Epidemiol 2003; 24:309-10 [author reply 310-2].
14. Edmond MB, Ober JF, Dawson ID, Weinbaum DL, Wenzel RP. Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality. Clin Infect Dis 1996; 23:1234-9.
15. Garbutt JM, Ventrapragada M, Littenberg B, Mundy LM. Association between resistance to vancomycin and death in cases of Enterococcus faecium bacteremia. Clin Infect Dis 2000; 30:466-72.
16. Shay DK, Maloney SA, Montecalvo M, et al. Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. J Infect Dis 1995; 172:993-1000.
17. Lucas GM, Lechtzin N, Puryear DW, Yau LL, Flexner CW, Moore RD. Vancomycin-resistant and vancomycin-susceptible enterococcal bacteremia: comparison of clinical features and outcomes. Clin Infect Dis 1998; 26:1127-33.
18. Peset V, Tallon P, Sola C, et al. Epidemiological, microbiological, clinical, and prognostic factors of bacteremia caused by high-level vancomycin-resistant Enterococcus species. Eur J Clin Microbiol Infect Dis 2000; 19:742-9.
19. Lodise TP, McKinnon PS, Tam VH, Rybak MJ. Clinical outcomes for patients with bacteremia caused by vancomycin-resistant enterococcus in a level 1 trauma center. Clin Infect Dis 2002; 34:922-9.
20. Bhavnani SM, Drake JA, Forrest A, et al. A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia. Diagn Microbiol Infect Dis 2000; 36:145-58.
21. Vergis EN, Hayden MK, Chow JW, et al. Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia: a prospective multicenter study. Ann Intern Med 2001; 135:484-92.
22. Linden PK, Pasculle AW, Manez R, et al. Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin Infect Dis 1996; 22:663-70.
23. DiazGranados CA, Jernigan JA. Impact of vancomycin resistance on mortality among neutropenic patients with enterococcal blood stream infections. J Infect Dis 2005; 191:588-95.
24. Mayhall CG. Control of vancomycin-resistant enterococci: it is important, it is possible, and it is cost-effective. Infect Control Hosp Epidemiol 2002; 23:420-3.
25. Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 2001; 54:1046-55.
26. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177-88.
27. Alderson P, Green S, Higgins JPT, eds. Cochrane reviewers' handbook 4.2.2. Updated March 2004. Available at: http://www.cochrane.org/resources/ handbook/hbook.htm. Accessed 31 January 2004.
28. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988; 16:128-40.
29. Mundy LM, Sahm DF, Gilmore M. Relationships between enterococcal virulence and antimicrobial resistance. Clin Microbiol Rev 2000; 13:513-22.
30. Arduino RC, Jacques-Palaz K, Murray BE, Rakita RM. Resistance of Enterococcus faecium to neutrophil-mediated phagocytosis. Infect Immun 1994; 62:5587-94.
31. Elsner HA, Sobottka I, Mack D, Claussen M, Laufs R, Wirth R. Virulence factors of Enterococcus faecalis and Enterococcus faecium blood culture isolates. Eur J Clin Microbiol Infect Dis 2000; 19:39-42.
32. Coque TM, Patterson JE, Steckelberg JM, Murray BE. Incidence of hemolysin, gelatinase, and aggregation substance among enterococci isolated from patients with endocarditis and other infections and from feces of hospitalized and community-based persons. J Infect Dis 1995; 171:1223-9.
33. Salgado CD, Farr BM. Outcomes associated with vancomycin-resistant enterococci: a meta-analysis. Infect Control Hosp Epidemiol 2003; 24:690-8.
34. Nosocomial enterococci resistant to vancomycin-United States, 1989-1993. MMWR Morb Mortal Wkly Rep 1993; 42:597-9.
35. Stosor V, Peterson LR, Postelnick M, Noskin GA. Enterococcus faecium bacteremia: does vancomycin resistance make a difference? Arch Intern Med 1998; 158:522-7.
36. Tornieporth NG, Roberts RB, John J, Hafner A, Riley LW. Risk factors associated with vancomycin-resistant Enterococcus faecium infection or colonization in 145 matched case patients and control patients. Clin Infect Dis 1996; 23:767-72.
37. Wells CL, Juni BA, Cameron SB, et al. Stool carriage, clinical isolation, and mortality during an outbreak of vancomycin-resistant enterococci in hospitalized medical and/or surgical patients. Clin Infect Dis 1995; 21:45-50.
38. Mainous MR, Lipsett PA, O'Brien M. Enterococcal bacteremia in the surgical intensive care unit: does vancomycin resistance affect mortality? The Johns Hopkins SICU Study Group. Arch Surg 1997; 132:76-81.
39. Krcmery V, Bilikova E, Svetlansky I, Kovacicova G. Is vancomycin resistance in enterococci predictive of inferior outcome of enterococcal bacteremia? Clin Infect Dis 2001; 32:1110-2.
40. Werner G, Klare I, Spencker FB, Witte W. Intra-hospital dissemination of quinupristin/dalfopristin- and vancomycin-resistant Enterococcus faecium in a paediatric ward of a German hospital. J Antimicrob Chemother 2003; 52:113-5.
41. Rahim S, Pillai SK, Gold HS, Venkataraman L, Inglima K, Press RA. Linezolid-resistant, vancomycin-resistant Enterococcus faecium infection in patients without prior exposure to linezolid. Clin Infect Dis 2003; 36:E146-8.
42. Dibo I, Pillai SK, Gold HS, et al. Linezolid-resistant Enterococcus faecalis isolated from a cord blood transplant recipient. J Clin Microbiol 2004; 42:1843-5.
43. Werner G, Cuny C, Schmitz FJ, Witte W. Methicillin-resistant, quinupristin-dalfopristin-resistant Staphylococcus aureus with reduced sensitivity to glycopeptides. J Clin Microbiol 2001; 39:3586-90.
44. Hershberger E, Donabedian S, Konstantinou K, Zervos MJ. Quinupristin-dalfopristin resistance in gram-positive bacteria: mechanism of resistance and epidemiology. Clin Infect Dis 2004; 38:92-8.
45. Spellberg B, Powers JH, Brass EP, Miller LG, Edwards JE Jr. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis 2004; 38:1279-86.